Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuelle Samalin

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Surgery|September 11, 2022
The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastasesLakhdar Khellaf, François Quénet, Marta Jarlier, et al.
The American Journal of Gastroenterology|August 28, 2004
Colonic flat neoplasia: frequency and concordance between endoscopic appearance and histological diagnosis in a French prospective seriesMarie-Danièle Diebold, Emmanuelle Samalin, Corinne Merle, et al.
BMJ Open|November 21, 2022
Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trialJean-Baptiste Trouiller, Bérengère Macabeo, Andrew Poll, et al.
Bulletin Du Cancer|March 7, 2015
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective studyÉmilie Soularue, Romain Cohen, Christophe Tournigand, et al.
BMC Cancer|September 30, 2009
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective studyAstrid Lièvre, Emmanuelle Samalin, Emmanuel Mitry, et al.
European Journal of Cancer (Oxford, England : 1990)|April 27, 2010
Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative studyJacqueline Duffour, Simon Thézenas, Olivier Dereure, et al.
The Oncologist|October 22, 2011
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trialEric Assenat, Francoise Desseigne, Simon Thezenas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 8, 2018
Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study)Aziz Zaanan, Emmanuelle Samalin, Thomas Aparicio, et al.
The Oncologist|January 15, 2026
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancerEmmanuelle Samalin, Hélène Senellart, Simon Thezenas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 7, 2011
Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre studyCatherine Le Roux, Catherine Lombard-Bohas, Christelle Delmas, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Surgery|September 11, 2022
The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastasesLakhdar Khellaf, François Quénet, Marta Jarlier, et al.
The American Journal of Gastroenterology|August 28, 2004
Colonic flat neoplasia: frequency and concordance between endoscopic appearance and histological diagnosis in a French prospective seriesMarie-Danièle Diebold, Emmanuelle Samalin, Corinne Merle, et al.
BMJ Open|November 21, 2022
Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trialJean-Baptiste Trouiller, Bérengère Macabeo, Andrew Poll, et al.
Bulletin Du Cancer|March 7, 2015
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective studyÉmilie Soularue, Romain Cohen, Christophe Tournigand, et al.
BMC Cancer|September 30, 2009
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective studyAstrid Lièvre, Emmanuelle Samalin, Emmanuel Mitry, et al.
European Journal of Cancer (Oxford, England : 1990)|April 27, 2010
Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative studyJacqueline Duffour, Simon Thézenas, Olivier Dereure, et al.
The Oncologist|October 22, 2011
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trialEric Assenat, Francoise Desseigne, Simon Thezenas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 8, 2018
Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study)Aziz Zaanan, Emmanuelle Samalin, Thomas Aparicio, et al.
The Oncologist|January 15, 2026
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancerEmmanuelle Samalin, Hélène Senellart, Simon Thezenas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 7, 2011
Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre studyCatherine Le Roux, Catherine Lombard-Bohas, Christelle Delmas, et al.
Pageof 7